Literature DB >> 28379310

Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction.

Wesley T O'Neal1, Pratik Sandesara1, Nikhil Patel2, Sanjay Venkatesh2, Ayman Samman-Tahhan1, Muhammad Hammadah1, Heval M Kelli1, Elsayed Z Soliman3,4.   

Abstract

AIMS: To determine if markers of diastolic dysfunction are associated with atrial fibrillation (AF) development among patients with heart failure with preserved ejection fraction (HFpEF). METHODS AND
RESULTS: We examined the association of several echocardiographic measures of diastolic dysfunction with incident AF in 573 patients (mean age = 68 ± 9.5 years; 48% men; 79% white) with HFpEF from the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT) who were free of baseline AF. Echocardiograms were analysed at a core laboratory. Incident AF cases were identified by follow-up study electrocardiograms and review of relevant medical records through May of 2013. Over a median follow-up of 3 years, 40 patients developed AF (incidence rate = 2.2 per 100 person years). Increasing values of the E/A ratio [per 0.1 increase: hazard ratio (HR) = 1.11, 95% confidence interval (CI) = 1.06-1.17], left atrial volume (per 5 mL increase: HR = 1.13, 95% CI = 1.03-1.23), and left atrial area (per 5 cm2 increase: HR = 1.51, 95% CI = 1.03-2.22) were associated with greater risk of AF. The risk of AF decreased with increasing peak A wave velocities (per 10 cm/s increase: HR = 0.83, 95% CI = 0.72-0.96). The risk of AF was not materially altered when peak A wave velocity was further adjusted for left atrial volume (HR = 0.83, 95% CI = 0.71-0.96) and area (HR = 0.83, 95% CI = 0.71-0.96). However, the associations of left atrial volume (HR = 1.10, 95% CI = 0.99-1.22) and area (HR = 1.48, 95% CI = 0.96-2.28) were no longer significant when accounting for peak A wave velocity.
CONCLUSION: Diastolic parameters of left atrial function possibly are more important markers of AF risk than left atrial dilation in HFpEF. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  atrial fibrillation; echocardiogram; heart failure; preserved ejection fraction

Mesh:

Substances:

Year:  2017        PMID: 28379310      PMCID: PMC5837728          DOI: 10.1093/ehjci/jex038

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  15 in total

Review 1.  Assessment of diastolic function.

Authors:  Miguel A Quiñones
Journal:  Prog Cardiovasc Dis       Date:  2005 Mar-Apr       Impact factor: 8.194

2.  Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy.

Authors:  L E Teichholz; T Kreulen; M V Herman; R Gorlin
Journal:  Am J Cardiol       Date:  1976-01       Impact factor: 2.778

3.  Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

Authors:  Marc A Pfeffer; Brian Claggett; Susan F Assmann; Robin Boineau; Inder S Anand; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; John F Heitner; Eldrin F Lewis; Eileen O'Meara; Jean-Lucien Rouleau; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Sonja M McKinlay; Bertram Pitt
Journal:  Circulation       Date:  2014-11-18       Impact factor: 29.690

4.  Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.

Authors:  Akshay S Desai; Eldrin F Lewis; Rebecca Li; Scott D Solomon; Susan F Assmann; Robin Boineau; Nadine Clausell; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Sonja McKinlay; Eileen O'Meara; Tamaz Shaburishvili; Bertram Pitt; Marc A Pfeffer
Journal:  Am Heart J       Date:  2011-11-08       Impact factor: 4.749

5.  Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women.

Authors:  Teresa S M Tsang; Bernard J Gersh; Christopher P Appleton; A Jamil Tajik; Marion E Barnes; Kent R Bailey; Jae K Oh; Cynthia Leibson; Samantha C Montgomery; James B Seward
Journal:  J Am Coll Cardiol       Date:  2002-11-06       Impact factor: 24.094

Review 6.  Atrial fibrillation pathophysiology: implications for management.

Authors:  Yu-ki Iwasaki; Kunihiro Nishida; Takeshi Kato; Stanley Nattel
Journal:  Circulation       Date:  2011-11-15       Impact factor: 29.690

7.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.

Authors:  Lars G Olsson; Karl Swedberg; Anique Ducharme; Christopher B Granger; Eric L Michelson; John J V McMurray; Margareta Puu; Salim Yusuf; Marc A Pfeffer
Journal:  J Am Coll Cardiol       Date:  2006-04-27       Impact factor: 24.094

8.  Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

Authors:  Sanjiv J Shah; John F Heitner; Nancy K Sweitzer; Inder S Anand; Hae-Young Kim; Brian Harty; Robin Boineau; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Eldrin F Lewis; Valetin Markov; Eileen O'Meara; Bondo Kobulia; Tamaz Shaburishvili; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Rebecca Li
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

9.  Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.

Authors:  Amil M Shah; Sanjiv J Shah; Inder S Anand; Nancy K Sweitzer; Eileen O'Meara; John F Heitner; George Sopko; Guichu Li; Susan F Assmann; Sonja M McKinlay; Bertram Pitt; Marc A Pfeffer; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2013-11-18       Impact factor: 8.790

10.  Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction.

Authors:  David D McManus; Grace Hsu; Sue Hee Sung; Jane S Saczynski; David H Smith; David J Magid; Jerry H Gurwitz; Robert J Goldberg; Alan S Go
Journal:  J Am Heart Assoc       Date:  2013-02-01       Impact factor: 5.501

View more
  4 in total

Review 1.  Imaging for Risk Stratification in Atrial Fibrillation with Heart Failure.

Authors:  Kennosuke Yamashita; Ravi Ranjan
Journal:  Cardiol Clin       Date:  2019-02-22       Impact factor: 2.213

2.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2021-05-22

Review 3.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; James Thomas; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28

Review 4.  Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop.

Authors:  Sana M Al-Khatib; Emelia J Benjamin; Christine M Albert; Alvaro Alonso; Cynthia Chauhan; Peng-Sheng Chen; Anne B Curtis; Patrice Desvigne-Nickens; Jennifer E Ho; Carolyn S P Lam; Mark S Link; Kristen K Patton; Margaret M Redfield; Michiel Rienstra; Yves Rosenberg; Renate Schnabel; John A Spertus; Lynne Warner Stevenson; Mellanie True Hills; Adriaan A Voors; Lawton S Cooper; Alan S Go
Journal:  Circulation       Date:  2020-06-08       Impact factor: 29.690

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.